OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts Screener

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

Officer exercised or converted 2,690 UTHR derivative securities | OQRO

Home
Insider trades
United Therapeutics
Officer exercised or converted 2,690 UTHR derivative securities

Insider trades

Insider trade

Officer exercised or converted 2,690 UTHR derivative securities

Traded Aug 20, 2026 · Filed Aug 22, 2026

UTHUnited TherapeuticsUTHR

2,690
Derivative units

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Aug 20, 2026
Reporting period: Not applicable
Filed with the SEC: Aug 22, 2026

OfficerOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001231589-26-000018

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Filed / recorded

Aug 22, 2026, 12:43 AM UTC

Added to OQRO

Oct 6, 2026, 9:34 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

UNITED THERAPEUTICS Corp

Issuer CIK

1082554

Ticker

UTHR

Reporting person

Paul A Mahon

Relationship

Officer

Officer title

EVP & GENERAL COUNSEL

Security

Stock Option

Table

Derivative (Table II)

Transaction date

Aug 20, 2026

Transaction code

Shares / units

2,690

Price per share

$0.00

Acquired / disposed

Disposed (D)

Shares owned after

Ownership form

Direct

Amendment

Footnotes from the filing

This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025.

Around the same time

Martine A RothblattChairperson & CEO

Filed 3w ago

9,500Shares · @ $117.76

Traded Sep 17 · filed 2 days later

Derivative exercise or conversion — not an open-market buy.

More Official record

Martine A Rothblatt (Chairperson & CEO) sold ~$295K of United Therapeutics

Scheduled in advanceFiled 3w ago

Martine A Rothblatt (Chairperson & CEO) sold ~$865K of United Therapeutics

Scheduled in advanceFiled 3w ago